In our August 2009 article titled “Treating Parkinson’s Disease: Investment Opportunities and Challenges,” we reviewed some of the historical challenges associated with developing treatments for Parkinson’s disease and cited reasons for optimism going forward in addition to highlighting several promising companies making progress. Since that time, many of the companies we featured have...
Read More »

Parkinson’s disease is one of the most common of the neurogenerative diseases affecting 1 in 100 people over the age of 60.  Approximately 1.5 million Americans currently suffer from the disease and it is estimated that 60,000 Americans are newly diagnosed each year.  PD is both a chronic and progressive disease. While the...
Read More »

Proteins are essential components of the human body.  They perform specific biological functions within a cell and each type of protein has a unique function. For example, enzymes are proteins that help biochemical reactions to occur within the body.  But before they can carry out these important functions, proteins must assemble into precise three-dimensional...
Read More »

Last week, the NASDAQ Biotech Index (NBI) declined more than 10 percent compared to an approximate 4.5 percent decline for the S&P 500. Since the NBI has been outperforming the broader market since mid-2008, this week’s relative underperformance came as quite a shock to many investors. Trying to explain the decline, most industry pundits...
Read More »